343 varieties have been included in the 2022 medical insurance catalog through preliminary review, and the four highlights are the first to see!

       On September 17. the State Medical Insurance Bureau officially released the List of Drugs Declared for Formal Review after the Adjustment of the Drug Catalogue of National Basic Medical Insurance, Work related Injury Insurance and Maternity Insurance in 2022.

　　On September 6. the State Medical Insurance Bureau released the List of Drugs and Related Information that have passed the Preliminary Formal Examination in 2022 for the Adjustment of the National Medical Insurance Drug Catalog. A total of 344 varieties have passed the preliminary examination, including 199 western drugs and Chinese patent drugs outside the catalog, and 145 western drugs and Chinese patent drugs within the catalog. The publicity time is one week (as of the 12th day).

　　Compared with the preliminary list, Harbin? Metronidazole vaginal expansion suppository of American Pharmaceutical is not on the official list. A total of 343 varieties in the official list have officially passed the preliminary review, including 198 western medicines and Chinese patent medicines not included in the list, and 145 western medicines and Chinese patent medicines included in the list.

　　This round of medical insurance negotiation has many points of view.

　　01 Nearly 90 types of oncology drugs were imported from the "Babang" PD - (L) 1 group "lost their voice"?

　　In terms of indications, the number of anti-tumor and immunomodulators included in the preliminary list is the largest, totaling 89.

　　From the preliminary list, there are Slulimab injection from Fuhong Hanlin, Envolimab injection from Kangning Jierui and Kadunilimab injection from Kangfang Biological.

　　Surprisingly, the imported PD - (L) 1 product, which has been running with us all the year round, was directly and collectively "lost its voice" in this medical insurance negotiation. Whether it is Pabolizumab from MSD, Navulizumab from BMS, Atilizumab from Roche, or Duvalizumab from AstraZeneca, all did not appear in the preliminary list.

　　02 The enthusiasm of foreign enterprises is soaring. Novartis has the largest number of products

　　This year, 9 enterprises applied for more than 5 drugs. Among them, Novartis Pharmaceuticals participated in this year's medical insurance negotiation with 14 drugs, becoming the enterprise with the largest number of drugs applied in this medical insurance negotiation.

　　Pfizer ranked second. This year, the number of drugs for medical insurance negotiation was 11. Among them, Pipercelli Capsules and Digarik Acetate for Injection were also listed in the preliminary review last year.

　　Sanofi (Beijing), AstraZeneca (Wuxi) and Chia Tai Tianqing applied for 7 drugs; The number of drugs declared by Bayer is 6; The number of drugs declared by Jiangsu Haosen and Baekje Shenzhou (Beijing) is 5.

　　03. The "sky high price" CAR-T products attracted more attention from traditional Chinese medicine enterprises and actively became the "New Year"

　　Mingjunuo brought the second domestic CAR-T product, Riceolencel Injection (Sinoda), which was approved for marketing in September 2021 and entered the medical insurance negotiation directory for the first time this year.

　　The online purchase price of 1290000 yuan/needle of Ricky Orensei injection is 90000 yuan more expensive than that of 1.2 million yuan/needle of Aquilensei injection of Fosun Kate. With the experience of Fosun Kate last year, Yaoming Junuo still takes the initiative to apply for medical insurance negotiation for pricing this time. Is it to attract flow, or is it really to be confident that the product price will be kept down and go to face the "soul bargaining" of medical insurance negotiation? "How much decline" has also become the focus of public attention

　　In this preliminary review catalog, what deserves attention in the field of Chinese patent medicine is that many enterprises such as Tianjin Tianshili and Jilin Huakang have brought paediatric drugs such as Shaoma Zhijing Granule and Shuqing Granule. While promoting the development of traditional Chinese medicine products, it also enriches the choice of paediatric drugs. It broke the limitation that only western medicine was used in pediatrics in the previous medical insurance catalogue.

　　04. Rare disease attracts attention again, Sanofi accelerates in an all-round way

　　In this year's preliminary review catalogue, on the basis of continuing to support innovative drugs, it also highlights the attention paid to drugs for treating rare diseases. According to statistics, there are nearly 20 drugs for rare diseases and rare diseases in the preliminary list.

　　Among them, Sanofi has the largest number of products, and four products have been shortlisted in the preliminary list, including arabinosidase for injection to treat Pompeii disease α、 Agarase for injection in Fabry disease β、 Concentrated solution of laronidase for injection in mucopolysaccharide storage disease, and imisidase for injection in Gaucher disease.

　　Local enterprises have also started to "march forward" in the field of rare diseases! Edu sulfatase injection for mucopolysaccharide storage disease type II of Nuo'ai Pharmaceutical, oral suspension of riluzole for amyotrophic lateral sclerosis developed by Guangzhou Zhaoke Lianfa Pharmaceutical, Nitiamino capsule for tyrosinemia type I of Hanguang Pharmaceutical, sodium phenylbutyrate granules for urea circulation disorder of Zhaoke Pharmaceutical, huperzine A injection for myasthenia gravis of Wanbang Pharmaceutical, Inelizumab injection in the treatment of optic neuromyelitis by Humon Pharmaceutical Co., Ltd.

　　Next, the State Medical Insurance Bureau will organize expert review and other work according to the requirements of the Interim Measures for the Administration of Medication under Basic Medical Insurance and the 2022 Work Plan for the Adjustment of the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue. Relevant enterprises are invited to pay attention to the "2022 National Medical Insurance Drug Directory Adjustment Application Module" of the national medical insurance service platform, and timely obtain relevant review, negotiation, agreement and other information from the National Medical Insurance Bureau.

Shandong Zhushi Pharmaceutical Group Co., Ltd., founded in 2003, has more than 5000 registered employees. After years of development, it has developed into a diversified industrial cluster integrating medical devices, polymers, cosmetics, health food, daily necessities and biological reagent production, enterprise management consulting and training, real estate economy, pharmaceutical transportation, pharmaceutical printing, etc.

Adhering to the concept of life, health and happiness, the Group provides you with full chain health services.

HOT

NEW